This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The primary objective of this project is to determine the biodistribution of 111ln-BU-12 in patients with refractory CD19+ leukemia. The secondary objectives are to determine the maximum tolerated dose (MTD) of 90-Y-BU-12, the human anti-mouse antibody (HAMA) response, and preliminarily define the antitumor activity of 90-Y-BU-12.
Showing the most recent 10 out of 724 publications